Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

As hedge funds dump tech stocks, these four high-yield dividend stocks make sense for investors regardless of age or ...

Equities research analysts at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for shares of ...